Here's what that looks like: The Retatrutide Escalation Protocol (Phase 2 Trial Structure) Weeks 1-4: 2 mg subcutaneous injection, once weekly Weeks 5-8: 4 mg once weekly Weeks 9-12: 8 mg once weekly Weeks 13-16: 12 mg once weekly (highest dose arm) Week 17+: Maintenance at the highest tolerated dose In the Phase 2 trial published in The New England Journal of Medicine , participants in the highest dose group (12 mg) lost a mean of 24.2% of body weight at 48 weeks
As a result, its not recommended to stop until you have the green light from your doctor
Brighten in the next few minutes
However, optimal success is associated with intravenous or subcutaneous injection , because these delivery methods have a high bioavailability
Pinch the skin to create a fold of subcutaneous tissue
You sit down to answer one email, then notice three browser tabs, a half-finished text, and the sudden urge to reorganize your desk instead